Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
IPO Year:
Exchange: NASDAQ
Website: atrioncorp.com
SC 13G/A - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
SC 13G - ATRION CORP (0000701288) (Subject)
SC 13G/A - ATRION CORP (0000701288) (Subject)
SC 13D - ATRION CORP (0000701288) (Subject)
SC 13D/A - ATRION CORP (0000701288) (Subject)
ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20
ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion's 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion's 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion
Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th
ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800
ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023. Commenting on the results for the first quarter of 2024 compared to the prior
ALLEN, Texas, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the fourth quarter ended December 31, 2023 and the full year 2023. For the fourth quarter of 2023 compared to the fourth quarter of 2022, revenues were $43.6 million, up $729 thousand, operating income was $6.7 million, down $2.1 million, and net income was $6.4 million, down $1.9 million. Fourth quarter 2023 diluted earnings per share were $3.65 compared to $4.70 for the fourth quarter of 2022. Commenting on 2023 quarterly results compared to the comparable 2022 periods, David Battat, President and CEO, stated, "Looking at the 2023 and comparable 2022 quarters sequentially, w
ALLEN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on December 15, 2023 to stockholders of record at the close of business on December 1, 2023. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact:Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800
ALLEN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the third quarter ended September 30, 2023. Revenues for the third quarter of 2023 totaled $41.9 million compared to $44.6 million for the same period in 2022. For the quarter ended September 30, 2023, operating income was $4.1 million, down $5.5 million from the comparable 2022 period, and net income was $2.9 million, down $5.9 million from the same period in 2022. Third quarter 2023 diluted earnings per share were $1.67 compared to $4.94 for the third quarter of 2022. Commenting on the results for the third quarter of 2023, David Battat, President and CEO, stated, "As was th
ALLEN, Texas, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) announced the election today of Jeannette Bankes as a director, effective immediately. Ms. Bankes brings to our Board over 32 years of experience at major medical device and pharmaceutical companies. Since March 2019, Ms. Bankes has served as the President and General Manager of the Global Surgical Franchise at Alcon Inc. From August 2004 to March 2019, Ms. Bankes served in leadership positions across multiple divisions and functions at Boston Scientific Corporation, including as General Manager, Urology and Pelvic Health. Prior to joining Boston Scientific, Ms. Bankes worked for Merck & Co. Ms. Bankes holds
ALLEN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced an increase in its quarterly cash dividend from $2.15 per share to $2.20 per share. At today's meeting, the Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on September 29, 2023, to stockholders of record at the close of business on September 15, 2023. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4/A - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
4 - ATRION CORP (0000701288) (Issuer)
15-12G - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
S-8 POS - ATRION CORP (0000701288) (Filer)
8-K - ATRION CORP (0000701288) (Filer)
8-K - ATRION CORP (0000701288) (Filer)
ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20
Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th
ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800
ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023. Commenting on the results for the first quarter of 2024 compared to the prior
ALLEN, Texas, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the fourth quarter ended December 31, 2023 and the full year 2023. For the fourth quarter of 2023 compared to the fourth quarter of 2022, revenues were $43.6 million, up $729 thousand, operating income was $6.7 million, down $2.1 million, and net income was $6.4 million, down $1.9 million. Fourth quarter 2023 diluted earnings per share were $3.65 compared to $4.70 for the fourth quarter of 2022. Commenting on 2023 quarterly results compared to the comparable 2022 periods, David Battat, President and CEO, stated, "Looking at the 2023 and comparable 2022 quarters sequentially, w
ALLEN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on December 15, 2023 to stockholders of record at the close of business on December 1, 2023. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact:Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800
ALLEN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the third quarter ended September 30, 2023. Revenues for the third quarter of 2023 totaled $41.9 million compared to $44.6 million for the same period in 2022. For the quarter ended September 30, 2023, operating income was $4.1 million, down $5.5 million from the comparable 2022 period, and net income was $2.9 million, down $5.9 million from the same period in 2022. Third quarter 2023 diluted earnings per share were $1.67 compared to $4.94 for the third quarter of 2022. Commenting on the results for the third quarter of 2023, David Battat, President and CEO, stated, "As was th
ALLEN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced an increase in its quarterly cash dividend from $2.15 per share to $2.20 per share. At today's meeting, the Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on September 29, 2023, to stockholders of record at the close of business on September 15, 2023. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800
ALLEN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2023. Revenues for the second quarter of 2023 totaled $43.8 million compared to $48.9 million for the same period in 2022. For the quarter ended June 30, 2023, operating income was $7.4 million, down $3.7 million from the comparable 2022 period, and net income was $6.6 million, down $2.8 million from the same period in 2022. Second quarter 2023 diluted earnings per share were $3.73 compared to $5.20 for the second quarter of 2022. Commenting on the results for the second quarter of 2023 compared to the prior year period, David Battat, Presiden
ALLEN, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock. This dividend will be payable on June 30, 2023 to stockholders of record at the close of business on June 15, 2023. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact:Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800
Headquartered in Allen, Texas, Atrion is a manufacturer of proprietary medical products, generating approximately $169 million in annual revenue in 2023. The $460.00 per share in cash price for Atrion represents a total transaction enterprise value of approximately $800 million. The transaction is expected to close prior to Nordson's fiscal year-end 2024
Atrion (NASDAQ:ATRI) reported quarterly earnings of $3.65 per share. This is a 22.34 percent decrease over earnings of $4.70 per share from the same period last year. The company reported $43.58 million in sales this quarter. This is a 1.70 percent increase over sales of $42.85 million the same period last year.
As of Jan. 8, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Harpoon Therapeutics, Inc. (NASDAQ:HARP) On Jan. 5, Oppenheimer analyst Hartaj Singh initiated co
Atrion Corporation (NASDAQ:ATRI) shares traded lower on Thursday. The stock took a break from its recent uptrend over the past few weeks, pulling back by over 4%. What To Know: Atrion stock reached a low in mid-November not seen since several years prior. The move lower coincided with the company's reporting of a year-over-year decrease in its third-quarter financial results. However, it was around the same time that shares began to trade higher, creating an uptrend during December. A one-month high in the stock's price was reached on Wednesday, followed by the pullback from the strength seen on Thursday. The stock's price action drew some attention during the session, as the ticker appea
Atrion (NASDAQ:ATRI) reported quarterly earnings of $1.67 per share. This is a 66.19 percent decrease over earnings of $4.94 per share from the same period last year. The company reported $41.91 million in sales this quarter. This is a 6.09 percent decrease over sales of $44.63 million the same period last year.
Atrion Corporation (NASDAQ:ATRI) today announced an increase in its quarterly cash dividend from $2.15 per share to $2.20 per share. At today's meeting, the Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on September 29, 2023, to stockholders of record at the close of business on September 15, 2023.
Atrion (NASDAQ:ATRI) reported quarterly earnings of $3.73 per share. This is a 28.27 percent decrease over earnings of $5.20 per share from the same period last year. The company reported $43.84 million in sales this quarter. This is a 10.32 percent decrease over sales of $48.88 million the same period last year.
Atrion (NASDAQ:ATRI) reported quarterly earnings of $1.98 per share. This is a 57.96 percent decrease over earnings of $4.71 per share from the same period last year. The company reported $39.99 million in sales this quarter. This is a 15.16 percent decrease over sales of $47.14 million the same period last year.